Well, considering the trial design was for stage 4 patients that had exhausted other treatment options, I would say that keeping a pancreatic cancer stable for three months when only having four cycles of K (four months of treatment if I am correct) is a pretty damn positive sign that K is working to a very good level. I am curious though, what is the timing of the stable disease as compared to the timing of the dosing? Was it concurrent, was it after the final dosing, or did it happen in a trailing manner as doses were administered? I don't know if that level of information has become available yet.
News 
Market Data 
Discover 
AI
